Immunizations

People can now receive an mRNA booster shot five months after completing their Pfizer-BioNTech primary series.

The “Shots for Tots” initiative combines Walgreens’ on-site vaccination clinics and vaccine literacy with programs happening at participating churches.

The Food and Drug Administration amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine, authorizing the use of a single booster dose for administration to individuals aged 16 and 17 years old.

PreHevbrio is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years old and older.

The FDA approved Seqirus’ multidose vial presentation for Audenz to help protect individuals aged six months old and older against influenza A(H5N1) in the event of a pandemic.

The CDC Advisory Committee on Immunization Practices has voted unanimously to recommend booster doses of Pfizer/BioNTech's and Moderna's COVID-19 vaccine for all adults six months after they finish their first two doses.

Moderna’s revised application, which was originally submitted in September, comes as the FDA is expected to authorize Pfizer-BioNTech’s booster shots for all adults as early as this week.

Approval would mean that any adult who received a second dose of the vaccine at least six months earlier would be able to get a booster.